Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162048

SCHEMBL10162048

SCHEMBL10162048

CC(=O)c1ccc2c(c1C)CC[C@@H]2NC(=O)c1cc(C(=O)NCc2ccc(F)c(C(F)F)c2)nc2c(F)cnn12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 7/20 0.73
▸ ADAMTS4 O75173 2/20 0.73
▸ MMP3 P08254 2/20 0.73
▸ MMP8 P22894 1/20 0.50
▸ MMP12 P39900 1/20 0.50
▸ ALDH1A1 P00352 5/20 0.36
▸ MAPK1 P28482 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TSHR P16473 2/20 0.34
▸ USP2 O75604 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ RPS6KA1 Q15418 1/20 0.34
▸ KLKB1 P03952 2/20 0.33
▸ HKDC1 Q2TB90 2/20 0.32
▸ MAPT P10636 1/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HPGD P15428 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10167280 0.94 MMP13 (0.81) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10161904 0.93 MMP13 (0.77) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10161973 0.92 MMP13 (0.76) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10161916 0.91 MMP13 (0.70) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10161931 0.91 MMP13 (0.74) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162149 0.91 MMP13 (0.70) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10161919 0.91 MMP13 (0.73) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162059 0.91 MMP13 (0.69) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162064 0.90 MMP13 (0.73) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10161954 0.90 MMP13 (0.73) MMP13ADAMTS4MMP3MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.